Researchers at Stanford have developed an inducible and programmable CRISPR-mediated transcript organization (CRISPR-TO) method for repositioning RNAs to various desired subcellular compartments.
Researchers at Stanford have developed methods to link antigenic or immunomodulatory molecules to bacterial surface proteins of commensal bacteria that result in a high immune response when applied to an epithelial surface of a mammal.
A team of Stanford researchers has developed humanized and chimeric mouse anti-human CD99 monoclonal antibodies with demonstrated activity against AML (acute myeloid leukemia) cells in vitro and in vivo.
Introduction: Blood cell transfusion plays a vital role in modern medicineāsupporting surgery, obstetrics, trauma care, and cancer chemotherapy. In the US alone, more than 12 million red-cell units are consumed annually.
Stanford Medicine's Ji Research Group has developed a simple, quantitative method for detecting and characterizing gene fusions that uses DNA rather than RNA as analyte.
Stanford scientists have created a de novo protein design platform that designs binding proteins that specifically target antigens in the major histocompatibility complex (MHC).
Non-alcoholic steatohepatitis (NASH) is the most common liver disease, leading to cirrhosis and hepatocellular carcinoma (HCC). HCC is one of the most common cancers and has a dismal prognosis as currently available medical treatment only improves survival by a few months.
Researchers at Stanford have identified a novel class of ribonucleic acid (RNA)-reactive groups that effectively modify the RNA by placing heteroaryl and aryl groups at the 2'-hydroxyl (OH) positions.
Researchers at Stanford University have discovered a first-in-class covalent inhibitor that binds to activated Fis1 and prevents mitochondrial fission and dysfunction.
Stanford scientists have developed a novel method to accelerate the development of T cell target probes known as Rapid Identification of Peptide-ligands from Protein Antigen (RIPPA).
Stanford researchers have developed a strategy for generating chimeric transcription factors that enables exhaustion-resistant CAR-T cells and can be generalized to a wide range of cell therapies.